(Q57271196)

1

object named as

Vincent Soriano

0 references

author name string

Antonio Madejon

2

0 references

Eugenia Vispo

3

0 references

Pablo Labarga

4

0 references

Javier Garcia-Samaniego

5

0 references

Luz Martin-Carbonero

6

0 references

Marcelle Bottecchia

8

0 references

Paula Tuma

9

0 references

Pablo Barreiro

Expert Opinion on Emerging Drugs

10

0 references

language of work or name

English

0 references

publication date

March 2008

0 references

published in

0 references

volume

13

0 references

page(s)

1-19

0 references

issue

1

0 references

cites work

Treatment of chronic hepatitis C infection with peginterferons plus ribavirin

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Production of infectious hepatitis C virus in tissue culture from a cloned viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

New therapeutic strategies for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Cyclophilin inhibitors in hepatitis C viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

The design of drugs for HIV and HCV

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Hepatitis C: molecular virology and antiviral targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

The hepatitis C virus life cycle as a target for new antiviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Characterization and mutational analysis of the helicase and NTPase activities of hepatitis C virus full-length NS3 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Structural Analysis of the Hepatitis C Virus RNA Polymerase in Complex with Ribonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Deoxycholic acid activates protein kinase C and phospholipase C via increased Ca2+ entry at plasma membrane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Ribavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2'-C-Methylcytidine, the Active Component of Valopicitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Adult onset type II citrullinemia as a cause of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

The culture of designing hepato-biliary randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Ribavirin: is it a mutagen for hepatitis C virus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.13.1.1